Zhili Powder Veterinary Grade API is supplied for downstream formulation into solid, liquid, and feed-delivered veterinary drug products. The powder is not a finished dosage form. Weight correction uses the dried-basis assay value: API charge (kg) = (target label claim per unit × number of units in batch) / (assay fraction × 1000). When the label claim is 20 mg per tablet and the dried-basis assay is 0.990, the charge for a 1,000,000-tablet batch is 20.20 kg before excipient adjustment. The scenarios below are restricted to real processing routes for veterinary tablets, injections, capsules, powders and granules, medicated premixes, and oral solution systems; each route includes the compliance standard, charge ratio, production process, and terminal product class.

Compression, Dilution Potential, and Disintegration Boundaries in Veterinary Tablet Manufacturing

In veterinary tablet production, Zhili Powder is rarely compressed as a direct-compression system unless the API particle size distribution and bulk density are in the range typical of spray-dried lactose: D90 ≤250 µm and Carr index ≤20. If the incoming powder has Carr index above 30, wet granulation is introduced because die fill variation at press speeds above 30 rpm produces unacceptable weight variability. The API addition is determined by the label claim, not by a fixed weight percentage: for a 1,000,000-tablet batch with a 20 mg claim and API assay 0.990, the charge is 20.20 kg. A formulation with total tablet weight 250 mg therefore uses 20.20 mg API per tablet, equivalent to 8.08% w/w before any overage. Overages must be justified by forced degradation data under ICH Q1A(R2) storage conditions and are not assumed. Direct compression blends are manufactured by screening croscarmellose sodium, microcrystalline cellulose PH102, lactose monohydrate, and Zhili Powder through a 20-mesh screen, blending in a bin blender at 10–15 rpm for 15 min, then adding magnesium stearate 0.5% w/w in a final 3 min cube blend. Compression on a rotary tablet press with B-tooling uses main compression force 10–25 kN, precompression force 5–8 kN, and tablet weight control to ±2.0%. Release criteria include USP <701> disintegration in water at 37 ± 2°C with a limit of 15 min for uncoated tablets, USP <905> acceptance value ≤15.0, USP <1216> friability ≤1.0%, and USP <711> dissolution if specified in the individual monograph. Terminal products include immediate-release uncoated tablets, film-coated tablets, and water-soluble boluses for ruminant administration; film coating is performed in a side-vented pan using an aqueous hydroxypropylmethylcellulose system at 40–50°C exhaust temperature.

Wet granulation is selected when published dry-compaction data for Zhili Powder is limited or when the API is sensitive to compression overload. Granulation uses hydroxypropylcellulose binder at 2.0–4.0% w/w dissolved in purified water, with granulation end point determined by torque rise on a high-shear granulator main impeller at 1.5–2.5 A above dry-mix baseline. Granules are dried in a fluid bed at inlet air temperature 50–60°C to loss on drying 1.5–2.5%, then milled through an oscillating granulator equipped with 14–18 mesh screens. The terminal tablet matrix must retain disintegration despite the granule binder; excessive binder above 4.0% w/w can delay disintegration past 15 min and is outside the acceptance window for immediate-release veterinary tablets.

What Limits Terminal Sterilization Selection for Veterinary Injectables Containing Heat-Labile API Powders?

Among the six downstream routes, the injection route imposes the narrowest process window because the finished dosage form must meet sterility, pyrogen, particulate, and pH specifications simultaneously. The choice between terminal steam sterilization at 121°C for 15 min and aseptic filtration through a 0.22 µm PVDF membrane depends on the thermal degradation kinetics of Zhili Powder in the final aqueous matrix. Published data for this specific configuration is limited; therefore, forced degradation studies at 80°C, 25°C/60% RH, and 40°C/75% RH must establish whether the API survives terminal sterilization without exceeding unspecified degradation product thresholds defined by the monograph or contract stability requirement. For a 100 L batch of a 50 mg/mL injection with API assay 0.985, the Zhili Powder charge is 5076 g after correction for salt factor and water content. The dissolution vessel uses water for injection at 20–25°C under nitrogen overlay; pH is adjusted with 0.1 M hydrochloric acid or 0.1 M sodium hydroxide to a target 4.5–7.5 window, with tonicity adjustment using sodium chloride to 280–320 mOsm/kg. Terminal products include 50 mL and 100 mL multi-dose vials and sterile powder for reconstitution. If the API is heat-labile, the solution is filtered through a 0.22 µm polyvinylidene fluoride filter under unidirectional airflow in an ISO 14644-1 Class 5 environment, filled into presterilized glass vials, and stoppered. Release includes USP <71> sterility, USP <85> bacterial endotoxin with the limit calculated as K/M, USP <788> particulate matter with ≥10 µm particles ≤6000 per container and ≥25 µm particles ≤600 per container for small-volume parenterals, USP <790> visible particulates, and USP <791> pH. Lyophilized cake production, if used, requires annealing at the glass transition temperature of the frozen matrix and chamber pressure 0.2–0.5 mbar with primary drying at −30°C to −20°C; these values are product-specific and cannot be transferred across formulations without thermal characterization.

Segregation in Capsule Filling Is Predicted by Flow Function Coefficient, Not Average Particle Size

When the drug loading in a hard gelatin capsule falls below 5.0% w/w of the final fill weight, segregation becomes the dominant content uniformity risk because fine API particles migrate through the void spaces between larger excipient carriers during machine vibration. A 250 mg hard gelatin capsule with a 10 mg label claim and API assay 1.000 has a drug load of 4.0% w/w; the API is first geometrically pre-blended with lactose monohydrate 200 mesh in a 1:1 ratio, then passed through a 30-mesh screen, and then diluted stepwise in a low-shear V-blender at 20–25 rpm for 20 min. If the flow function coefficient is below 4, dry granulation by slugging or roller compaction is used to increase particle size and reduce the segregation tendency. Filling on a dosator-type encapsulator with pin diameter 8–12 mm and fill weight control ±2.0% produces capsules that must meet USP <905> content uniformity acceptance value ≤15.0, USP <701> disintegration 30 min for hard gelatin capsules, and USP <711> dissolution where the individual veterinary monograph requires. Terminal products include hard gelatin capsules and hydroxypropylmethylcellulose capsules for companion animals, as well as open-and-sprinkle oral capsule formats for dosing in feed or water; these are not intended for parenteral use.

Dry powder and granule processing for oral use is controlled by particle size distribution, moisture uptake, and bulk density rather than by high-precision compaction or sterility assurance. For a 500 mg unit-dose oral granule with a 100 mg label claim and API assay 0.980, the Zhili Powder charge is 102.0 mg per unit, which is 20.41% w/w of the total granule mass. The API is pre-blended with a 1:1 dilution of microcrystalline cellulose and sucrose, then granulated in a top-spray fluid bed with a hydroxypropylmethylcellulose binder solution at 2.0% w/w solids, inlet air temperature 50–60°C, and final granule moisture 1.5–2.5%. Granules are passed through a 16-mesh screen to remove oversize material and collected as the 16–60 mesh fraction; bulk density is typically 0.42–0.58 g/cm³, though published data for Zhili Powder-specific granule density is limited. Release testing uses USP <811> powder fineness by sieve analysis, loss on drying ≤2.5%, and content uniformity USP <905> where the product is supplied in unit-dose sachets. Terminal product types include oral powders in sachets, in-bottle powder for reconstitution, and oral granules administered by mixing into feed or water. The same process train, without fluid-bed granulation, is used for simple oral powders when the bulk drug is already free-flowing and the label claim permits direct fill.

When Carryover Limits and Premix Homogeneity Are Governed by 21 CFR 225 and ISO 6497

In medicated premix manufacturing, the largest batch masses and the most demanding homogenization requirement arise because the active component is distributed through a carrier that will be further diluted in Type B and Type C feed products. The API addition ratio is defined by the final feed concentration and the inclusion rate of the premix. A premix labeled at 10.0% w/w active strength contains 10.0 kg Zhili Powder per 100 kg total premix; when that premix is added at 10 kg per metric tonne of complete feed, the resulting feed concentration is 1000 mg/kg if the premix assay is 100%. The batch is prepared by charging ground corncob or calcium carbonate carrier into a ribbon mixer, spraying mineral oil at 0.3–0.5% w/w as a dust suppressant, and mixing at 10–12 rpm for 10–15 min. Sampling follows ISO 6497, with homogeneity acceptance commonly set as coefficient of variation ≤5.0% across 10 sampling points. Carryover is managed by validated cleanout procedures under 21 CFR 225 and by sequence matrices that place the lightest carrier before the next product batch. Terminal products include Type A premix, Type B intermediate premix, and Type C medicated feed; finished feed production must comply with 21 CFR 558 for new animal drugs used in feed. Published data for carryover limits of Zhili Powder in specific ribbon mixers is limited, so equipment-specific flush and sequence matrices are generated during installation qualification rather than borrowed from another API.

From pH Drift to Preservative Demand: Oral Solution Design Parameters

Scaling a co-formulated oral solution from laboratory batch to 500 L production tank exposes pH drift and preservative demand as the two controlling variables over the labeled storage period. For a 20 mg/mL co-formulated oral solution batch of 500 L with API assay 0.990, the Zhili Powder charge is 10.10 kg. The API is dissolved in purified water at 20–25°C with propylene glycol as a co-solvent at 5–15% v/v; buffer salts are selected after pH-stability screening, and pH is adjusted to a target that preserves both chemical stability and antimicrobial activity of the preservative system. Multidose containers require USP <51> antimicrobial effectiveness testing, while release includes USP <791> pH, USP <785> osmolality, and HPLC assay per the individual monograph. The solution is clarified through a 1.2 µm prefilter and a 0.45 µm membrane, filled into high-density polyethylene bottles with induction-sealed caps, and visually inspected for precipitate. Terminal product types include oral drench solutions, concentrated drinking water solutions diluted before administration, and aqueously soluble oral solution formulations; if the product is presented as a powder for oral solution, the solution-after-reconstitution is tested for clarity and pH after 24 h under ambient conditions. Published data for Zhili Powder's preservative compatibility with parabens and sorbic acid under commercial storage is limited; preservative efficacy testing must be generated for the exact formula rather than inferred from another dosage form.